Efficacy of twice daily application of LEO 124249 ointment 30 mg/g for 12 weeks on eyebrow alopecia areata. Exploratory Phase 2a

Registry ID

EUCTR2017-002720-24

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE2

Sponsor

LEO Pharma A/S

Start date

2017-10-17

Completion date

2018-05-16

Last update

2026-08-16

Conditions

• Alopecia Areata

Summary

To evaluate the efficacy of twice daily topical LEO 124249 ointment 30 mg/g compared with LEO 124249 ointment vehicle on hair growth in subjects with Alopecia Areata on eyebrows.

Locations

• , , Denmark

Related clinical trials

• A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
• A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
• An Observational Study of Patients With Dermatologic Disease
• A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
• Serum Ferroptosis Biomarkers (GPX4, MDA) in Alopecia Areata
• Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib

View on source registry